Key clinical point: A new index of frailty predicts survival in older patients with multiple myeloma based on accumulation of aging-associated deficits, rather than on chronological age alone.
Major finding: Median overall survival was 26.8 months for patients classified as frail, vs. 43.7 months for nonfrail patients (P = .015).
Study details: Retrospective analysis of 2.7 million records of noncancer patients to create an index subsequently validated in records for 305 patients with newly diagnosed multiple myeloma (aged 66 years and older).
Disclosures: The research was supported by National Cancer Institute. Authors reported disclosures related to Celgene, Janssen, Amgen, Takeda, and Carevive Systems.
Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.
This Week's Must Reads
Must Reads in Multiple Myeloma
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.
Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.